|
| |
|
Dr. AMIT MISRA |
|
| |
|
|
Sr. Principal Scientist and In-charge; Pharmaceutics
Division
Associate Professor, AcSIR
CSIR-Central Drug Research Institute
Sector 10-A Janakipuram Extension
Nauwakhera, Sitapur Road
Lucknow 226031, UP, India
E-mail: amit_misra{a}cdri.res.in
Scopus Author ID: 35776846400
Researcher ID: C-4199-2012
Full Curriculum Vitae |
|
| |
| Educational qualifications |
M.Pharm. Ph.D. |
| Date of Birth |
15.06.1965 |
|
| |
| CURRENT
AREAS OF INTEREST |
| |
| • |
Our lab is working on drug and vaccine delivery systems along lines followed by hundreds of researchers worldwide. We like to think we are different, because we get to work with CSIR-CDRI compounds in the discovery pipeline and we follow three guiding principles:
Any (reasonable) amount of drug can be delivered to any (reasonably distinct) tissue or cell site, within any (reasonable) time window—the ‘why’ is more interesting than the ‘how’ of drug delivery.
Drug delivery is not the end of the problem—the fun starts after drug delivery is achieved.
Delivery systems proposed by us should be industrially scalable; dirt cheap (not merely cost-effective); and relevant to diseases of socio-economically challenged people.
We collaborate with:
U.D. Gupta and Pushpa Gupta at NJIL, Agra, for work on tuberculosis;
KS Venkatesh for computation and mathematical modeling, and with Dhirendra S Katti on particulate systems; both at IIT Kanpur; and
Rajiv Garg at KGMU for work on humans.
We have been generously funded by CSIR, DST, the Royal Society, UK, and corporate donors. Most lab members are affiliated with the Open Source Drug Discovery Initiative.
At this time, we can only accommodate trainees from M. Pharm. (Pharmaceutics) students of NIPER, Rae Bareli. |
|
| |
| RESEARCH PROJECTS |
| |
• |
Tuberculosis
Malaria
Diabetes
Contraception
Particles
Transdermals |
|
| |
| RESEARCH GROUP |
| |
• |
Heikham Kajal Devi, SRF.
Mradul Mohan, SRF.
Atul Kumar Agrawal, SRF.
Anuradha Gupta, SRF.
Sanketkumar Pandya, SRF. |
|
| |
| COURSES TAUGHT (AcSIR, JNU, NIPER) |
| |
• |
Cellular and Molecular Evolution; The Major Histocompatibility Complex; Drug delivery systems;
Drug Regulatory Affairs |
|
| |
| RESEARCH FACILITIES |
| |
• |
Spray-dryer, high-pressure homogenizer, Liposome extruder etc. for delivery system fabrication.
Tangential flow filtration, centrifuges, freeze-dryer, rotary evaporators etc. for isolation
HPLC, HPTLC, DSC-TGA, Stability chambers, Mastersizer, Zetasizer, Microplate reader, gradient PCR, BSL-3 cell culture facility. |
|
| |
| CAREER HIGHLIGHTS |
| |
• |
The “Eat-a-banana-sideways” award in B. Pharm; 1987.
R&D Pharmacist at Trends Pharma, Bombay, 1989-90.
Staff Scientist-I at the National Institute of Immunology, New Delhi, 1991-92
DST Young Scientist, 1997 |
|
| |
| SELECTED
PUBLICATIONS |
| |
• |
Particulate pulmonary delivery systems containing anti-tuberculosis agents.
Anuradha Gupta, Sanketkumar M Pandya, Mohammad Imran, Atul K Agrawal, Mradul Mohan, Amit Misra
Crit Rev Ther Drug Carrier Syst. 2013;30(4):277-91. |
|
• |
Inhalable microparticles of nitric oxide donors induce phagosome maturation and kill M. tuberculosis.
Rahul Kumar Verma, Atul Kumar Agrawal, Amit Kumar Singh, Mradul Mohan, Anuradha Gupta, Pushpa Gupta, Umesh Datta Gupta, Amit Misra
Tuberculosis (Edinb.) 2013, doi:pii: S1472-9792(13)00020-6. 10.1016/j.tube.2013.02.012.. |
|
• |
Pharmacogenomic involvement of HLA-DRB1*1501 and vitamin D receptor polymorphism with survival of Mycobacterium tuberculosis in human macrophages exposed to inhalable microparticles containing isoniazid and rifabutin.
Amit K Singh, Abhimanyu, Awadh B Yadav, Sandeep Sharma, Rajiv Garg, Mridula Bose and Amit Misra
Pharmacogenomics 2013;14(5):531-40 |
|
• |
Inhaled microparticles containing clofazimine are efficacious in the treatment of experimental tuberculosis in mice.
Rahul Verma, Willem Germishuizen, M Portia Motheo, Atul Agrawal, Amit Singh, Mradul Mohan, Pushpa Gupta, Umesh Gupta, Moloko Cholo, Ronald Anderson, P Bernard Fourie, and Amit Misra
Antimicrob Agents Chemother. 2013; 57(2):1050-2. |
|
• |
Inhalable Microparticles Containing Nitric Oxide Donors: Saying NO to Intracellular Mycobacterium tuberculosis.
Rahul K. Verma, Amit K. Singh, Mradul Mohan, Atul K. Agrawal, Priya R. P. Verma, Anuradha Gupta, and Amit Misra.
Mol Pharmaceutics 2012; 9(11):3183-9. |
|
• |
Episodic transdermal delivery of testosterone.
Ritu Malik, KS Venkatesh, Anil Kumar Dwivedi and Amit Misra.
Mol Pharmaceutics 2012 9(6):1537-43. |
|
• |
Partial biodistribution and pharmacokinetics of isoniazid and rifabutin following pulmonary delivery of inhalable microparticles to rhesus macaques.
Rahul Kumar Verma, Jatinder Kaur Mukker, Ravi Shankar Prasad Singh, Kaushlendra Kumar, Priya Ranjan Prasad Verma and Amit Misra.
Mol Pharmaceutics 2012; 9(4):1011-6. |
|
• |
Inhaled therapies for tuberculosis and the relevance of activation of lung macrophages by particulate drug delivery systems. Rahul Kumar Verma, Amit Kumar Singh, Mradul Mohan, Atul Kumar Agrawal, Amit Misra.
Therapeutic Delivery 2011; 2(6): 753–768. |
|
• |
Biodegradable Nanoparticles in the Murine Vagina: Trans-Cervical Retrograde Transport and Induction of Proinflammatory Cytokines. Ritu Malik, J. P. Maikhuri, Gopal Gupta, and Amit Misra. J. Biomed Nanotechnol. 20117(1): 45-46 |
|
• |
Loading and Release of Amphotericin-B from Biodegradable Poly(lactic-co-glycolic acid) Nanoparticles. Rahul K. Verma, Sanket Pandya, and Amit Misra.
J. Biomed Nanotechnol. 2011;7(1): 118-120 |
|
• |
Preparation of Tetanus Toxoid and Ovalbumin Loaded Gliadin Nanoparticles for Oral Immunization. Heikham Kajal and Amit Misra.
J. Biomed Nanotechnol. 2011;7(1):211-212 |
|
• |
Nanoparticles Containing Nitric Oxide Donor with Antileishmanial Agent for Synergistic Effect Against Visceral Leishmaniasis. Sanket Pandya, Rahul K. Verma, and Amit Misra.
J. Biomed Nanotechnol.2011;7(1): 213-215 |
|
• |
Nanoparticles Containing Nitric Oxide Donor with Antileishmanial Agent for Synergistic Effect Against Visceral Leishmaniasis. Sanket Pandya, Rahul K. Verma, and Amit Misra.
J. Biomed Nanotechnol.2011;7(1): 213-215 |
|
• |
The Devil’s Advocacy: When and Why Inhaled Therapies for Tuberculosis May Not Work. Awadh Bihari Yadav, Amit K. Singh, Rahul K. Verma, Mradul Mohan, Atul K. Agrawal and Amit Misra
Tuberculosis (Edinb) 2011;91(1):65-66. |
|
• |
Inhaled drug therapy for treatment of tuberculosis. Amit Misra,* Anthony J. Hickey, Carlo Rossi, Gerrit Borchard, Hiroshi Terada, Kimiko Makino; P. Bernard Fourie, Paolo Colombo
Tuberculosis (Edinb)2011;91(1):71-81. |
|
| |
| |
| |
|
| |
|